Shape Therapeutics

Shape Therapeutics, Inc. (ShapeTx) was founded in 2018 and is headquartered in Seattle, Washington, USA. The company is committed to researching RNA-editing gene therapies. Its next-generation gene therapy platform can advance the development of treatments for neurodegenerative diseases, cancer, metabolic disorders, and rare genetic conditions. Shape has developed a human stable cell line technology for AAV production, which surpasses standard expression methods, with the aim of applying these technologies to research activities targeting various genetic disease treatments. The Shape AAVid capsid discovery platform enables direct screening of billions of engineered AAV variants in non-human primates (NHP). It also employs AI-driven bioinformatics to identify characteristics influencing tissue tropism and accelerate the creation of higher-efficacy gene therapies.